CTOs on the Move

HealthMyne

www.healthmyne.com

 
The HealthMyne Quantitative Imaging Decision Support (QIDS)® software platform and its Rapid Precise Metrics (RPM)™ functionality transform multiple clinical decision support workflows by combining quantitative imaging metrics with relevant patient information.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

HealthMyne raised $15M on 08/01/2018

Similar Companies

Metro Record Svc

Metro Record Svc is a Burbank, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Curio Wellness

Founded in 2014 in Baltimore, Maryland, Curio Wellness is a cGMP certified, vertically integrated medical cannabis company and trusted healthcare partner. Recognized as the leading wellness brand in cannabis by BDS Analytics, Curio is committed to serving patients with targeted, effective, and reliable cannabis-based medicine.

Med MatRx

Med MatRx is a Monaca, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Outbound AI

Outbound AI is Conversation AI built for healthcare. Founded in 2021, the Seattle-based startup is breaking new ground with cloud technologies that serve as workforce multipliers to drive productivity while improving the daily job experience for human talent. The company`s inaugural offering includes a portfolio of intelligent Virtual Agents specially trained to streamline phone-based administrative work across the revenue cycle, including claims status, eligibility and benefits verification, prior authorization and more. Outbound AI is led by a passionate team of health and voice tech veterans and backed by several preeminent venture capital firms.

Sarepta

Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare diseases. Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in Limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth (CMT) and CNS-related disorders, reaching a total of over 20 therapies in various stages of development. The Company`s programs span across several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is poised to be the most meaningful precision genetic medicine company in the world and make a profound difference in the lives of patients suffering from rare neuromuscular diseases and other rare diseases.